Delaying surgery after neoadjuvant chemoradiotherapy improves prognosis of rectal cancer

Table 5 Effect of factors on overall survival and disease-free survival

	OS		DFS
	P value	HR with 95%CI	P value	HR with 95%CI
Sex	0.61	0.97, 95%CI: 0.19-4.99	0.69	0.50, 95%CI: 0.46-4.46
Age	0.57	1.01, 95%CI: 0.95-1.08	0.60	1.00, 95%CI: 0.94-1.06
Tumor localization	0.53	0.97, 95%CI: 0.72-1.30	0.88	1.17, 95%CI: 0.80-1.70
Pre-treatment stage	0.94	0.77, 95%CI: 0.80-7.50	0.45	0.90, 95%CI: 0.80-1.50
Pre-treatment T stage	0.59	1.08, 95%CI: 0.21-5.48	0.39	0.39, 95%CI: 0.15-3.02
Post-treatment stage	0.01	18.07, 95%CI: 0.60-53.9	0.007	0.82, 95%CI: 0.10-6.23
Post-treatment T stage	0.13	0.62, 95%CI: 0.34-11.3	0.07	0.25, 95%CI: 0.19-8.54
Postoperative metastatic lymph node (+)	0.001	0.91, 95%CI: 0.69-1.20	0.001	1.25, 95%CI: 0.93-1.67
Pathologic TRG	0.11	0.90, 95%CI: 1.28-6.35	0.04	1.19, 95%CI: 0.17-8.41

DFS: Disease-free survival; OS: Overall survival; TRG: Tumor regression grade.